Drugs, Investigational

"Drugs, Investigational" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.

Descriptor ID	D015507
MeSH Number(s)	D26.371
Concept/Terms	Drugs, Investigational Drugs, Investigational Investigational New Drugs Drugs, Investigational New New Drugs, Investigational Investigational Drugs

Below are MeSH descriptors whose meaning is more general than "Drugs, Investigational".

Chemicals and Drugs [D]
Pharmaceutical Preparations [D26]
Drugs, Investigational [D26.371]

Below are MeSH descriptors whose meaning is related to "Drugs, Investigational".

Below are MeSH descriptors whose meaning is more specific than "Drugs, Investigational".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drugs, Investigational" by people in this website by year, and whether "Drugs, Investigational" was a major or minor topic of these publications.

Bar chart showing 30 publications over 17 distinct years, with a maximum of 5 publications in 2009 and 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
2000	0	1	1
2003	0	1	1
2004	1	0	1
2007	0	1	1
2008	2	0	2
2009	3	2	5
2010	4	1	5
2011	1	0	1
2012	1	0	1
2013	1	0	1
2015	1	1	2
2016	1	0	1
2017	2	0	2
2018	1	1	2
2019	1	1	2
2020	1	0	1

Below are the most recent publications written about "Drugs, Investigational" by people in Profiles.

Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020 09; 19(9):727-737.

View in: PubMed
Bruinooge SS, Sherwood S, Grubbs S, Schilsky RL. Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. J Oncol Pract. 2019 11; 15(11):575-583.

View in: PubMed
Venanzi Rullo E, Ceccarelli M, Condorelli F, Facciol? A, Visalli G, D'Aleo F, Paolucci I, Cacopardo B, Pinzone MR, Di Rosa M, Nunnari G, Pellican? GF. Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review). Mol Med Rep. 2019 Mar; 19(3):1987-1995.

View in: PubMed
Moerdler S, Zhang L, Gerasimov E, Zhu C, Wolinsky T, Roth M, Goodman N, Weiser DA. Physician perspectives on compassionate use in pediatric oncology. Pediatr Blood Cancer. 2019 03; 66(3):e27545.

View in: PubMed
Malatack JJ, Doyle D. A Drug Regimen for Progressive Familial Cholestasis Type 2. Pediatrics. 2018 01; 141(1).

View in: PubMed
Goldberg RM, Wei L, Fernandez S. The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs. Oncologist. 2017 09; 22(9):1015-1019.

View in: PubMed
Klein-Szanto AJ, Bassi DE. Proprotein convertase inhibition: Paralyzing the cell's master switches. Biochem Pharmacol. 2017 09 15; 140:8-15.

View in: PubMed
Hanley CM, Robinson VM, Kowey PR. Status of Antiarrhythmic Drug Development for Atrial Fibrillation: New Drugs and New Molecular Mechanisms. Circ Arrhythm Electrophysiol. 2016 Mar; 9(3):e002479.

View in: PubMed
Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, Carini C, Creeke P, Davidson J, De Vries N, Finco D, Fogdell-Hahn A, Havrdova E, Hincelin-Mery A, C Holland M, H Jensen PE, Jury EC, Kirby H, Kramer D, Lacroix-Desmazes S, Legrand J, Maggi E, Maill?re B, Mariette X, Mauri C, Mikol V, Mulleman D, Oldenburg J, Paintaud G, R Pedersen C, Ruperto N, Seitz R, Spindeldreher S, Deisenhammer F. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. Clin Exp Immunol. 2015 Sep; 181(3):385-400.

View in: PubMed
Orloff M, Valsecchi ME, Sato T. Successes and setbacks of early investigational drugs for melanoma. Expert Opin Investig Drugs. 2015; 24(8):993-7.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement